Source:http://linkedlifedata.com/resource/pubmed/id/11551421
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2-3
|
| pubmed:dateCreated |
2001-9-11
|
| pubmed:abstractText |
This trial was initiated to evaluate the toxicity and activity of combination chemotherapy employing cisplatin (CDDP), docetaxel (DCT) and ifosfamide (IFX) in non-small cell lung cancer (NSCLC), and to determine the maximum tolerated dose (MTD) of IFX. Chemotherapy-naive patients with advanced or recurrent NSCLC received 60 mg/m(2) DCT followed after a 3-h interval by 60 mg/m(2) CDDP on chemotherapy day 1, and IFX at an escalating dose with mesna protection on days 2-4. The chemotherapy was repeated every 3 weeks. Granulocyte colony-stimulating factor (GCSF) was administered in the event of grade 3 leukopenia/neutropenia. The patients tolerated the treatment well up to level 4 of IFX dosing 1.5 g/day, but not the IFX dose at level 6 (2.0 g/day). Additional patients were enrolled in level 5 (IFX 1.7 g/day) to evaluate the toxicity of the drugs around the MTD. Level 5 was also judged as having exceeded the MTD, with febrile neutropenia and hepatic toxicity being observed as the dose-limiting toxicities. No toxicity-related deaths occurred. The majority of the chemotherapy courses were supported by GCSF administration. A total of 33 eligible patients were entered into the trial; the overall response rate was 10/33 or 30% among all eligible cases, and the rate for patients treated with the MTD or higher (levels 4-6) was 8/24, or 33% (90% confidence limit: 18-52%). The MTD of IFX was 1.5 g/m(2) administered for 3 days in this triplet combination. The clinical activity does not seem to justify the toxicity profile.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Ifosfamide,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0169-5002
|
| pubmed:author |
pubmed-author:AkiyamaYY,
pubmed-author:GotoKK,
pubmed-author:KodamaTT,
pubmed-author:KubotaKK,
pubmed-author:KunitohHH,
pubmed-author:KusabaHH,
pubmed-author:NihoSS,
pubmed-author:NishiwakiYY,
pubmed-author:OheYY,
pubmed-author:SaijoNN,
pubmed-author:SekineII,
pubmed-author:ShinkaiTT,
pubmed-author:TamuraTT,
pubmed-author:YamamotoNN
|
| pubmed:issnType |
Print
|
| pubmed:volume |
33
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
259-65
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11551421-Adolescent,
pubmed-meshheading:11551421-Adult,
pubmed-meshheading:11551421-Aged,
pubmed-meshheading:11551421-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11551421-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:11551421-Cisplatin,
pubmed-meshheading:11551421-Dose-Response Relationship, Drug,
pubmed-meshheading:11551421-Female,
pubmed-meshheading:11551421-Humans,
pubmed-meshheading:11551421-Ifosfamide,
pubmed-meshheading:11551421-Infusions, Intravenous,
pubmed-meshheading:11551421-Lung Neoplasms,
pubmed-meshheading:11551421-Male,
pubmed-meshheading:11551421-Maximum Tolerated Dose,
pubmed-meshheading:11551421-Middle Aged,
pubmed-meshheading:11551421-Neoplasm Recurrence, Local,
pubmed-meshheading:11551421-Paclitaxel,
pubmed-meshheading:11551421-Taxoids
|
| pubmed:articleTitle |
A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancer.
|
| pubmed:affiliation |
Department of Medical Oncology, National Cancer Center Hospital: 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. hkkunito@gan2.ncc.go.jp
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|